Peer-reviewed veterinary case report
Two dogs with immune anemia fully recovered after combined drug
By Yuki, Masashi et al.·Published in Open veterinary journal·2023·Yuki Animal Hospital, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Complete remission of two canine cases with precursor-targeted immune-mediated anemia after combination therapy with prednisolone, cyclosporine, and oclacitinib.
- Species:
- dog
Plain-English summary
Two dogs suffering from severe anemia due to a condition called precursor-targeted immune-mediated anemia (PIMA) were brought in for treatment. Initially, they received blood transfusions and a combination of medications, including prednisolone and cyclosporine, but these did not help. After adding oclacitinib, a newer medication that targets immune responses, both dogs showed significant improvement and achieved complete remission from their anemia. This suggests that oclacitinib could be a helpful option for dogs with PIMA that don't respond to standard treatments.
People also search for: dog anemia treatment · oclacitinib for dogs · immune-mediated anemia in dogs
Abstract
BACKGROUND: Precursor-targeted immune-mediated anemia (PIMA) has been described in dogs presenting with nonregenerative anemia and evidence of ineffective erythropoiesis. Although it has been suggested that its occurrence may be related to the immune targeting of erythroid precursors, this pathogenesis has not been established. PIMA is mainly treated with glucocorticoids, and in cases where glucocorticoids alone are not effective, immunosuppressants are also used as combination therapy. However, not all cases of PIMA go into remission after these treatments. CASE DESCRIPTION: Two dogs with severe nonregenerative anemia diagnosed as PIMA based on the results of clinical pathological examinations, including bone marrow examination, were treated with whole-blood transfusion and immunosuppressive doses of prednisolone, mycophenolate mofetil, and cyclosporine. However, these treatments failed to achieve remission of PIMA. Therefore, concomitant administration of oclacitinib, which is a Janus kinase-1 inhibitor that has been applied recently to the treatment of immune-mediated diseases, was performed; this combined regimen improved the anemia and achieved complete remission of PIMA. CONCLUSION: Oclacitinib may be an option for the treatment of PIMA in dogs failing to achieve remission with conventional immunosuppressive therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37842117/